NAIROBI, Kenya, Mar 17 – UK drugmaker GlaxoSmithKline Limited (GSK) has rebranded to Haleon Kenya Limited, effective March 14, 2025.
The rebrand comes after GSK transferred its consumer health business to Haleon to focus on innovative drugs.
Haleon will now encompass consumer health brands including Sensodyne, Panadol, Eno, and Scott’s Emulsion.
“This transition represents more than just a name change; it’s a reaffirmation of our commitment to delivering high-quality, science-driven health solutions tailored specifically for Kenyan consumers,” said Mark Pfister, General Manager for Haleon Sub-Saharan Africa.
“As Haleon, we are intensifying our focus on innovation, developing products that combine trusted science with a deep understanding of human needs to meet the evolving healthcare demands of Kenyans.”
As part of the rebranding process, the company’s product packaging will gradually transition from featuring the GSK logo to the Haleon logo, with some variations in branding expected on store shelves during this period.
